Virus vectors have been employed as gene transfer vehicles for various pre-clinical and clinical gene therapy applications. Replication-competent herpes simplex virus (HSV) vectors that replicate specifically in actively dividing glial tumor cells have been used in Phase I-II human trials in patients with glioblastoma multiforme (GBM), a fatal form of brain cancer. Research during the last decade on the development of HSV vectors has resulted in the engineering of recombinant vectors that are totally replication defective, non-toxic, and capable of long-term transgene expression. This chapter describes methods for the construction of recombinant genomic HSV vectors based on the HSV-1 replication-defective vector backbones, steps in their purification, and their small-scale production for use in cell culture experiments as well as studies in animals. © 2008 Humana Press, Totowa, NJ.
CITATION STYLE
Goins, W. F., Krisky, D. M., Wechuck, J. B., Huang, S., & Glorioso, J. C. (2008). Construction and production of recombinant herpes simplex virus vectors. Methods in Molecular Biology, 433, 97–113. https://doi.org/10.1007/978-1-59745-237-3_6
Mendeley helps you to discover research relevant for your work.